FDMT Q1 2020 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$427M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+60.1% YoY

Gross Profit

-$10M-272.2% margin

Operating Income

-$13M-375.6% margin

Net Income

-$13M-372.3% margin

EPS (Diluted)

$-0.89

QoQ Revenue Growth

+74.1%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$0

Total Liabilities

$0

Stockholders' Equity

$30M

Cash & Equivalents

-$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+60.1%
Gross Profit	-$10M	-$6M	-53.1%
Operating Income	-$13M	-$9M	-52.1%
Net Income	-$13M	-$8M	-59.4%